Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cognex Corporation is a scientific & technical instruments business based in the US. Cognex Corporation shares (CGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Cognex Corporation employs 2,055 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$87.25|
|52-week range||$57.10 - $101.59|
|50-day moving average||$87.10|
|200-day moving average||$82.84|
|Wall St. target price||$93.07|
|Dividend yield||$0.235 (0.26%)|
|Earnings per share (TTM)||$1.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-1.79%|
|1 month (2021-08-24)||0.05%|
|3 months (2021-06-24)||6.38%|
|6 months (2021-03-24)||12.58%|
|1 year (2020-09-24)||42.59%|
|2 years (2019-09-24)||85.20%|
|3 years (2018-09-24)||47.98%|
|5 years (2016-09-23)||70.88%|
Valuing Cognex Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cognex Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cognex Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 52x. In other words, Cognex Corporation shares trade at around 52x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cognex Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.04. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cognex Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Cognex Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $351 million.
The EBITDA is a measure of a Cognex Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$982.9 million|
|Operating margin TTM||33.36%|
|Gross profit TTM||$604.6 million|
|Return on assets TTM||10.35%|
|Return on equity TTM||21.69%|
|Market capitalisation||$15.7 billion|
TTM: trailing 12 months
There are currently 2.4 million Cognex Corporation shares held short by investors – that's known as Cognex Corporation's "short interest". This figure is 10.6% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Cognex Corporation shares can be evaluated.
Cognex Corporation's "short interest ratio" (SIR) is the quantity of Cognex Corporation shares currently shorted divided by the average quantity of Cognex Corporation shares traded daily (recently around 651049.72527473). Cognex Corporation's SIR currently stands at 3.64. In other words for every 100,000 Cognex Corporation shares traded daily on the market, roughly 3640 shares are currently held short.
However Cognex Corporation's short interest can also be evaluated against the total number of Cognex Corporation shares, or, against the total number of tradable Cognex Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cognex Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cognex Corporation shares in existence, roughly 10 shares are currently held short) or 0.0139% of the tradable shares (for every 100,000 tradable Cognex Corporation shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cognex Corporation.
Find out more about how you can short Cognex Corporation stock.
Dividend payout ratio: 1.28% of net profits
Recently Cognex Corporation has paid out, on average, around 1.28% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.26% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cognex Corporation shareholders could enjoy a 0.26% return on their shares, in the form of dividend payments. In Cognex Corporation's case, that would currently equate to about $0.235 per share.
While Cognex Corporation's payout ratio might seem low, this can signify that Cognex Corporation is investing more in its future growth.
Cognex Corporation's most recent dividend payout was on 2 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 18 August 2021 (the "ex-dividend date").
Cognex Corporation's shares were split on a 2:1 basis on 3 December 2017. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cognex Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cognex Corporation shares which in turn could have impacted Cognex Corporation's share price.
Over the last 12 months, Cognex Corporation's shares have ranged in value from as little as $57.1024 up to $101.5941. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cognex Corporation's is 1.6397. This would suggest that Cognex Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cognex Corporation provides machine vision products that capture and analyze visual information in order to automate manufacturing and distribution tasks worldwide. Its machine vision products are used to automate the manufacturing and tracking of discrete items, including mobile phones, aspirin bottles, and automobile tires by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process. The company offers VisionPro software, a suite of patented vision tools for advanced programming; Cognex Designer that allows customers to build vision applications with a graphical, flowchart-based programming environment; and Cognex deep learning vision software. It also provides a range of inspection tasks, including part location, identification, measurement, assembly verification, and robotic guidance; and vision sensors for vision applications, such as checking the presence and size of parts; the In-Sight product line of vision systems and sensors. In addition, the company offers ID products comprising DataMan image-based barcode readers and barcode verifiers. It sells its products to consumer electronics, automotive, consumer products, food and beverage, pharmaceuticals, and medical devices industries, as well as through a network of distributors and integrators. The company was founded in 1981 and is headquartered in Natick, Massachusetts.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.